http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CL-2019003533-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05cab2e54be5b03e7dd673d323c4ada0
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
filingDate 2019-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df7a8805d9c453b3df8fd58a7cf3f015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b721df6debe06f2ed7c22871da899f89
publicationDate 2020-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CL-2019003533-A1
titleOfInvention Use of vibegron to treat overactive bladder.
abstract THIS DISCLOSURE REFERS TO AN OVERACTIVE BLADDER TREATMENT METHOD THAT INCLUDES ADMINISTERING BY THE ORAL ROUTE TO A SUBJECT IN NEED OF AN AMOUNT OF FROM APPROXIMATELY 60 MG TO ABOUT APPROXIMATELY 90 MG (FOR EXAMPLE OF ABOUT 75 MG, FOR EXAMPLE, EXAMPLE OF VIEW). THIS DISCLOSURE ALSO REFERS TO A PHARMACEUTICAL UNIT DOSAGE COMPOSITION, RANGE FROM APPROXIMATELY 60 MG TO APPROXIMATELY 90 MG (FOR EXAMPLE, APPROXIMATELY 75 MG) OF VIBEGRON FOR ORAL ADMINISTRATION.
priorityDate 2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413592487
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44472635

Total number of triples: 30.